PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
<div><p>Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, which shows resistance to common breast cancer therapies, as it lacks the expression of the most common breast cancer targets. Therefore, TNBC treatment remains a challenge. Targeting programmed ce...
Saved in:
| Main Author: | Reem Saleh (3513056) (author) |
|---|---|
| Other Authors: | Rowaida Z. Taha (8854754) (author), Varun Sasidharan Nair (5396393) (author), Nehad M. Alajez (7397276) (author), Eyad Elkord (5396390) (author) |
| Published: |
2019
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
by: Reem Saleh (3513056)
Published: (2019) -
Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
by: Reem Saleh (3513056)
Published: (2019) -
Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
by: Afsheen Raza (492657)
Published: (2023) -
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
by: Remy Thomas (702843)
Published: (2021) -
Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
by: Maha, Al-Asmakh
Published: (2020)